Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS) | Small Molecules
Hits: 1013 The trial failed to meet its primary endpoint of complete remission (CR) rate CR rate was 53% higher in eprenetapopt with AZA arm compared to AZA alone, but did not reach statistical significance BOSTON, MA, USA I December 28, 2020 I Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine (AZA) v...
Source: pipelinereview.com
